Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits

vcsPRAsset_1316082_107174_709b5f24-efab-40f7-a95a-0fb2c84b5906_0.jpg

Patients show improvements in blood vessels and physical ability after 8-week regimen

— While exercise offers benefits for a wide range of health conditions, it has historically been considered too dangerous for people living with sickle cell disease (SCD). However, a new study published today in the journal Blood adds to mounting evidence that low-to moderate-intensity exercise may be not only safe, but beneficial for these patients.

SCD affects how blood flows through the body. For those with SCD, strenuous physical activity increases blood flow and can lead to serious complications including heart problems and episodes of severe pain known as vaso-occlusive crises. While many patients are advised to avoid all forms of exercise, the new study adds to mounting evidence that lower intensity exercise could actually be helpful.

“When physical exercise is tailored to be light-to-moderate in intensity, the risk of problems is limited,” said lead study author Laurent Messonnier, Ph.D., of the Université Savoie Mont Blanc in France. “Performed regularly, this type of exercise may induce beneficial muscle microvascular and functional adaptations that improve patients’ physical abilities and quality of life.”

The researchers recruited 40 patients with SCD and randomly assigned them to two groups. Half followed their normal lifestyle, which included little physical activity apart from everyday routines such as walking to the bus stop or grocery shopping. The other half participated in an individually tailored regimen of moderate-intensity 40-minute sessions on a stationary bicycle three times per week. Researchers monitored participants’ exertion levels closely during each exercise session, tracking circulating oxygen (saturation), blood lactate levels, and perceived exertion to ensure that participants maintained a moderate level of intensity throughout.

After eight weeks, the researchers took biopsies of muscle tissue from participants’ thighs. Among the 32 participants for whom complete data were available, the muscle biopsies revealed a significant increase in the density of small blood vessels known as capillaries, the number of capillaries around the muscle fiber, and the surface area through which oxygen and nutrients can flow between blood and muscle in participants who had exercised.

Previous studies have found SCD can cause blood vessels in muscle to become fewer. The changes observed in this study suggest moderate-intensity exercise may help counteract some of these effects, according to researchers, which should improve blood and oxygen delivery to tissues.

Participants in the exercise group also had significant improvements in their muscle function and overall physical ability. Some anecdotally reported improvements in sleep, concentration, and social interactions, as well.

Dr. Messonnier emphasized that further research is needed to understand the benefits—and risks—of exercise in patients with SCD. In this study, no adverse events requiring hospital admission occurred in the training group.

“The recent literature argues in favor of promotion of endurance exercise training for patients with SCD,” he said. “However, we need to stay cautious. Before any exercise, people with SCD should be tested and receive professional guidance on what level of exercise will be safe and appropriate.”

The study represents an initial attempt to determine whether moderate-intensity exercise is safe, feasible, and potentially beneficial in people living with SCD, but is limited by its small sample size and short duration. Researchers suggested future studies could explore the use of exercise in a larger, more diverse group of participants, determine effects of a longer training period, and investigate the impact of exercise on a broader range of clinical outcomes. 

# # #

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.

Contact:
Leah Enser
American Society of Hematology
lenser@hematology.org; 202-552-4927

Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits

Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits

Cancer-News

2 weeks
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
21 Views
Cancer-News 21 hours
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 23 hours
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
9 Views
kidneycancer 1 day
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 1 day
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 2 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 2 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
9 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 2 days
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
10 Views
kidneycancer 3 days